Taro Pharma (TARO) Tops Q4 EPS by 24c

Taro Pharma (NYSE: TARO) reported Q4 EPS of $0.54, $0.24 better than the analyst estimate of $0.30. Revenue for the quarter came in at $157.15 million versus the consensus estimate of $154.91 million.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Cuprina to buy seven-clinic Singapore healthcare group for S$4M
• Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'